부르가다 증후군 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Brugada Syndrome Market size is expected to reach USD 4.26 Billion in 2034 from USD 2.08 Billion (2025) growing at a CAGR of 8.29% during 2026-2034.

The Global Brugada Syndrome Market is growing as awareness and diagnosis of this rare genetic heart disorder improve worldwide. Brugada syndrome is associated with abnormal heart rhythms that can lead to sudden cardiac arrest if not properly managed. Advancements in cardiac diagnostics and increased understanding of genetic heart diseases have helped improve early detection and treatment options for patients.

Key drivers of the market include growing research into genetic cardiac disorders and improvements in electrocardiogram (ECG) screening methods. Healthcare providers are increasingly focusing on early identification of high-risk patients through genetic testing and cardiac monitoring. In addition, advancements in implantable cardiac devices have improved the management of patients diagnosed with this condition.

Looking ahead, the market is expected to expand with further developments in genetic research and personalized medicine. Enhanced diagnostic technologies and improved treatment protocols will help physicians better manage the condition and prevent life-threatening complications. As awareness of inherited heart conditions grows, the Brugada syndrome market is anticipated to see gradual but consistent growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Diagnosis Methods

• Electrocardiogram (ECG)
• Echocardiogram
• Electrophysiological (EP) Testing and Mapping
• Others (Genetic Testing, etc.)

By Treatment Type

• Surgical Methods
• Drug Therapy

By Indication Type

• Brugada Type 1
• Brugada Type 2

By End-user

• Hospitals & Clinics
• Surgical Centers
• Diagnostic Centers
• Ambulatory Surgical Centers
• Others (Research Institutes, etc.)

COMPANIES PROFILED

• GeneDx LLC, GE HealthCare, GSK plc, Lilly India, Boston Scientific Corporation, Pfizer Inc, Medtronic plc, Abbott Laboratories, Biotronik SE Co KG, Johnson Johnson via Biosense Webster
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BRUGADA SYNDROME MARKET: BY DIAGNOSIS METHODS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diagnosis Methods
• 4.2. Electrocardiogram (ECG) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Echocardiogram Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Electrophysiological (EP) Testing and Mapping Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others (Genetic Testing, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BRUGADA SYNDROME MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Type
• 5.2. Surgical Methods Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BRUGADA SYNDROME MARKET: BY INDICATION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication Type
• 6.2. Brugada Type 1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Brugada Type 2 Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BRUGADA SYNDROME MARKET: BY END-USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Ambulatory Surgical Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others (Research Institutes, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BRUGADA SYNDROME MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Diagnosis Methods
  • 8.2.2 By Treatment Type
  • 8.2.3 By Indication Type
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Diagnosis Methods
  • 8.3.2 By Treatment Type
  • 8.3.3 By Indication Type
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Diagnosis Methods
  • 8.4.2 By Treatment Type
  • 8.4.3 By Indication Type
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Diagnosis Methods
  • 8.5.2 By Treatment Type
  • 8.5.3 By Indication Type
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Diagnosis Methods
  • 8.6.2 By Treatment Type
  • 8.6.3 By Indication Type
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BRUGADA SYNDROME INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 GeneDx LLC
  • 10.2.2 GE HealthCare
  • 10.2.3 GSK Plc
  • 10.2.4 Lilly India
  • 10.2.5 Boston Scientific Corporation
  • 10.2.6 Pfizer Inc
  • 10.2.7 Medtronic Plc
  • 10.2.8 Abbott Laboratories
  • 10.2.9 Biotronik SE & Co. KG
  • 10.2.10 Johnson & Johnson (Via Biosense Webster)